It is thought that several carcinogens and tumour promoters act through the constitutive activation of NF-kB [16, 43], which induces the resistance of cancer cells to chemotherapeutic

agents and radiation [44]. The balance between proliferation and cell death is a decisive factor in the progression or inhibition of carcinogenesis, and a variety of mechanisms can be activated or inactivated to induce apoptosis [33]. Antioxidant molecules that have a thiol group, such as NAC, have the ability to promote several of these mechanisms in different types of human tumours [13, 45]. One of these mechanisms refers to upregulation of pro-apoptotic genes together with the downregulation of inhibitors of apoptosis genes, often accompanied by increased AZD0530 in vitro permeability of the mitochondrial membrane and release of cytochrome c, activating the caspase cascade. And all of these events are regulated by activation or inactivation of NF-kB [24, 46, 47].

Data from the present study confirm the findings of previous studies that showed a decrease in the expression of the p65 subunit using NAC or IFN-α [31, 48–53]. More importantly, combined treatment further reduced levels of p65 in a synergistic way, again suggesting that NAC and IFN-α act in different pathways. Since several genes involved in the initiation, promotion Ganetespib ic50 and tumour progression are regulated by NF-kB and its activation suppresses apoptosis and promotes cell proliferation [16, 54], the rational design of treatments that decrease NF-kB activity is a good strategy to treat malignancies, as observed here. Confirming the involvement of NF-kB on the effect of NAC, we found that cells Selleckchem GSK1120212 transfected with siRNA for the p65 (KD cells) had the same response of cells treated only with

NAC. Furthermore, KD cells treated with IFN-α had the same response as the combined treatment with NAC plus IFN-α while knockdown of NF-kB did not alter the sensitivity to NAC. Altogether, these data suggest that Osimertinib the increase in growth inhibition shown by NAC is probably due to the inhibition of NF-kB pathway. Even though it has been shown that IFN-α may have a role in blocking the NF-kB activating pathway triggered by the hepatitis B virus [51], this was not observed in our experiments. IFN-α treatment alone showed only a slight decrease in NF-kB activation, suggesting that IFN-α may act through different mechanisms depending on cell type and context. In conclusion, NAC potentiates the antitumoural effect of IFN-α, decreasing cell viability, increasing apoptosis and decreasing the expression of the p65 subunit of NF-kB.